MoonLake Immunotherapeutics (MLTX) Income from Continuing Operations (2021 - 2026)

MoonLake Immunotherapeutics' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 69707000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 71.87% year-over-year to 69707000.0; the TTM figure through Mar 2026 stood at 259470000.0 (down 75.52% YoY), while the FY2025 annual figure was 230321000.0, down 89.96% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 69707000.0, down from 63018000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 7887273.0 in Q4 2023, with the low at 70694000.0 in Q3 2025.
• The 5-year median for Income from Continuing Operations is 17416329.0 (2022), against an average of 31168061.71.
• Peak annual rise in Income from Continuing Operations reached 69.3% in 2022, while the deepest fall reached 20715.22% in 2022.
• MoonLake Immunotherapeutics' Income from Continuing Operations stood at 16467930.0 in 2022, then soared by 52.11% to 7887273.0 in 2023, then plunged by 488.23% to 46395000.0 in 2024, then sank by 35.83% to 63018000.0 in 2025, then fell by 10.61% to 69707000.0 in 2026.
• Business Quant data shows MLTX's Income from Continuing Operations at 69707000.0 in Q1 2026, 63018000.0 in Q4 2025, and 70694000.0 in Q3 2025.